157 related articles for article (PubMed ID: 19584197)
1. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?
Klibanski A
J Clin Endocrinol Metab; 2009 Jul; 94(7):2247-9. PubMed ID: 19584197
[No Abstract] [Full Text] [Related]
2. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
3. Pituitary gland: can prolactinomas be cured medically?
Molitch ME
Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
[TBL] [Abstract][Full Text] [Related]
4. Giant prolactinomas: Multi-modal approach to achieve tumor control.
Shimon I
Endocrine; 2017 May; 56(2):227-228. PubMed ID: 28050685
[No Abstract] [Full Text] [Related]
5. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
6. Resistant prolactinomas.
Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
[TBL] [Abstract][Full Text] [Related]
7. When to discontinue treatment of prolactinoma?
Wass JA
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
[No Abstract] [Full Text] [Related]
8. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
9. Management of prolactinomas.
Molitch ME; Thorner MO; Wilson C
J Clin Endocrinol Metab; 1997 Apr; 82(4):996-1000. PubMed ID: 9100563
[No Abstract] [Full Text] [Related]
10. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
11. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
[No Abstract] [Full Text] [Related]
12. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
14. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
15. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
16. Practical classification of prolactinomas for clinical use.
Delgrange E; Donckier JE
J Clin Endocrinol Metab; 2001 Apr; 86(4):1838-9. PubMed ID: 11297630
[No Abstract] [Full Text] [Related]
17. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long?
Guitelman M
Front Horm Res; 2006; 35():88-101. PubMed ID: 16809925
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
20. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
